Free Triiodothyronine (Free T3)
Free T3 measures the active, unbound thyroid hormone that binds nuclear thyroid hormone receptors (TR-alpha and TR-beta) with 10- to 15-fold greater affinity than T4.
Standard vs. Optimal Reference Rangespg/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
2.3 - 4.2 pg/mL
General reference distribution across unselected commercial populations.
3.2 - 4.0 pg/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Derived ~80% from peripheral 5'-deiodination of T4 in liver, kidney, and skeletal muscle by DIO1 and DIO2. T3 binds TRs to induce transcription of genes governing ATP consumption, UCP1 thermogenesis, and cardiac chronotropy.
Differential Diagnosis
Elevated Levels (Free T3 High)
- •Hyperthyroidism / T3 thyrotoxicosis
- •Exogenous liothyronine (Cytomel) administration
Low Levels (Free T3 Low)
- •Non-thyroidal illness syndrome (Euthyroid Sick Syndrome)
- •Caloric restriction / Starvation
- •Systemic inflammatory state / High IL-6
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Blood draw must occur strictly between 7:00 AM and 9:00 AM to account for steep circadian cortisol and testosterone peaks. Ensure 8 hours of restful sleep prior; night shift work or sleep deprivation severely blunts endocrine pulsatility. Discontinue biotin supplements for 72 hours before thyroid or steroid testing to prevent false immunoassay results. For reproductive hormones in premenopausal females, precisely document the day of the menstrual cycle (Day 3 for baseline follicular, Day 21 for luteal).
Reflexive Testing Protocol:
- Free Hormone Equilibrium Dialysis or LC-MS/MS assay for direct bioavailable hormone quantification
- Pituitary trophic hormone panel (TSH, LH, FSH, ACTH, Prolactin) to differentiate primary vs central secondary endocrinopathies
- Autoantibody quantification (Thyroid Peroxidase Antibodies, Thyroglobulin Antibodies, 21-Hydroxylase Antibodies)
- Pelvic, testicular, or thyroid high-resolution ultrasound imaging to assess glandular parenchymal architecture
- Dynamic endocrine stimulation testing (Cosyntropin/ACTH stimulation test, Dexamethasone suppression test, GnRH test)
Clinical Citations & Primary Literature (1)
- [1]Non-Thyroidal Illness Syndrome: Cellular Mechanisms and Clinical Outcomes - Lancet Diabetes & Endocrinology (2021). PMID: 33878250
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Free Triiodothyronine (Free T3) into overall healthspan optimization.